RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$88.23
+2.39%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$87.04
From 52W high−24.99%
Volume378783.00
Market cap$6.07B
P/E (TTM)—
P/S (TTM)25.3x
Div yield—
Key dataOct 19, 2026
Open
$87.04
From 52W high
−24.99%
Volume
378783.00
Market cap
$6.07B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−31.7x
P/E (TTM)
—
RSI (14)
36.2
MomentumView details →
1D Return
+2.39%
YTD Return
−17.33%
SummaryUpdated Jun 1, 2026
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company founded in 2008 and headquartered in Boston, Massachusetts. The company went public in October 2017 and focuses exclusively on developing and commercializing therapeutics for rare genetic diseases of obesity. Rhythm has successfully transitioned from a development-stage company to a commercial enterprise with its flagship product IMCIVREE, which targets specific genetic pathways that control hunger and weight regulation. The company operates in the highly specialized field of rare genetic obesity disorders, serving patients with conditions that were previously considered untreatable.
Similar companies
Latest newsMore news →
Kuehn Law, PLLC is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. breached their fiduciary duties to shareholders.21d agoRhythm Pharmaceuticals announced that it and its collaborators will present three posters and three oral presentations on setmelanotide in rare MC4R pathway diseases at the 64th Annual European Society for Paediatric Endocrinology Meeting in Marseille, France, September 8-10, 2026.40d ago